BioTime Reports Fourth Quarter and Fiscal 2017 Results
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today reported financial results for the fourth quarter and fiscal year ended December 31, 2017. “2017 was a successful year for BioTime, capped by our recent European CE Mark submission of Renevia® and approval by the DSMB to proceed with the initiation of Cohort 4 of the OpRegen® clinical trial,” said Adi Mohanty, Co-Chief Executive Officer of BioTime.